Tomohiro Enokida

1.3k total citations
60 papers, 703 citations indexed

About

Tomohiro Enokida is a scholar working on Oncology, Otorhinolaryngology and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Tomohiro Enokida has authored 60 papers receiving a total of 703 indexed citations (citations by other indexed papers that have themselves been cited), including 27 papers in Oncology, 26 papers in Otorhinolaryngology and 25 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Tomohiro Enokida's work include Head and Neck Cancer Studies (26 papers), Thyroid Cancer Diagnosis and Treatment (13 papers) and Salivary Gland Tumors Diagnosis and Treatment (10 papers). Tomohiro Enokida is often cited by papers focused on Head and Neck Cancer Studies (26 papers), Thyroid Cancer Diagnosis and Treatment (13 papers) and Salivary Gland Tumors Diagnosis and Treatment (10 papers). Tomohiro Enokida collaborates with scholars based in Japan, United States and Indonesia. Tomohiro Enokida's co-authors include Makoto Tahara, Nina Bhardwaj, Susumu Okano, Tomoko Yamazaki, Takao Fujisawa, Corina E. Dutcus, Kenji Nakano, Kazuhisa Toda, Alvaro Moreira and Yoshinori Imamura and has published in prestigious journals such as Journal of Clinical Investigation, Nature Communications and Journal of Clinical Oncology.

In The Last Decade

Tomohiro Enokida

45 papers receiving 689 citations

Peers

Tomohiro Enokida
Amy Prawira Canada
Yu Heng China
Wen Gao China
Antonella Ingrosso Italy
Venessa Tsang Australia
V. Papadimitrakopoulou United States
Hitomi Suzuki Japan
Mariachiara Santorsola Italy
Xiuyi Zhi China
Mary Kate Kasler United States
Amy Prawira Canada
Tomohiro Enokida
Citations per year, relative to Tomohiro Enokida Tomohiro Enokida (= 1×) peers Amy Prawira

Countries citing papers authored by Tomohiro Enokida

Since Specialization
Citations

This map shows the geographic impact of Tomohiro Enokida's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Tomohiro Enokida with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Tomohiro Enokida more than expected).

Fields of papers citing papers by Tomohiro Enokida

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Tomohiro Enokida. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Tomohiro Enokida. The network helps show where Tomohiro Enokida may publish in the future.

Co-authorship network of co-authors of Tomohiro Enokida

This figure shows the co-authorship network connecting the top 25 collaborators of Tomohiro Enokida. A scholar is included among the top collaborators of Tomohiro Enokida based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Tomohiro Enokida. Tomohiro Enokida is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Kiguchi, Yuya, Yukie Kashima, Lucky Ronald Runtuwene, et al.. (2025). Giant extrachromosomal element “Inocle” potentially expands the adaptive capacity of the human oral microbiome. Nature Communications. 16(1). 7397–7397.
2.
Enokida, Tomohiro, Shingo Sakashita, Nobukazu Tanaka, et al.. (2025). Concordance of BRAF V600E mutation between immunohistochemistry and genomic testing for thyroid cancer. International Journal of Clinical Oncology. 30(6). 1143–1151. 1 indexed citations
3.
4.
Enokida, Tomohiro, Susumu Okano, Takao Fujisawa, et al.. (2024). Clinical impact of a dose-escalation strategy for lenvatinib in differentiated thyroid cancer. International Journal of Clinical Oncology. 29(10). 1435–1443.
5.
Suzuki, Shinya, Atsunobu Sagara, Tomohiro Enokida, et al.. (2023). Impact of lenvatinib-induced proteinuria and renal dysfunction in patients with thyroid cancer. Frontiers in Oncology. 13. 1154771–1154771. 5 indexed citations
6.
Enokida, Tomohiro, Susumu Okano, Takao Fujisawa, et al.. (2023). 2228P Long-term clinical outcomes of Lenvatinib in patients with differentiated thyroid cancer: Results from the real-world practice of a single institution. Annals of Oncology. 34. S1147–S1147. 2 indexed citations
7.
8.
Tajiri, Kazuko, Shinya Suzuki, Tomohiro Enokida, et al.. (2023). Association between baseline blood pressure and the incidence of lenvatinib‐induced hypertension in patients with thyroid cancer. Cancer Medicine. 12(22). 20773–20782. 4 indexed citations
9.
Enokida, Tomohiro, Shinya Suzuki, Takao Fujisawa, et al.. (2023). A pharmacist-led opioid de-escalation program after completion of chemoradiotherapy in locally advanced head and neck cancer. Frontiers in Oncology. 13. 1145323–1145323.
10.
Enokida, Tomohiro, Susumu Okano, Masanobu Sato, et al.. (2023). Proton pump inhibitors and antibiotics adversely effect the efficacy of nivolumab in patients with recurrent or metastatic squamous cell carcinoma of the head and neck. European Journal of Cancer. 184. 30–38. 6 indexed citations
11.
Tanaka, Hideki, Tomohiro Enokida, Susumu Okano, et al.. (2023). Subsequent chemotherapy with paclitaxel plus cetuximab-based chemotherapy following immune checkpoint inhibitor in recurrent or metastatic squamous cell carcinoma of the head and neck. Frontiers in Oncology. 13. 1221352–1221352. 4 indexed citations
12.
Enokida, Tomohiro, Susumu Okano, Takao Fujisawa, et al.. (2023). Weekly paclitaxel, carboplatin and cetuximab (PCE) combination followed by nivolumab for recurrent and/or metastatic squamous cell carcinoma of the head and neck (R/M SCCHN). Oral Oncology. 147. 106615–106615. 1 indexed citations
13.
14.
Enokida, Tomohiro, Alvaro Moreira, & Nina Bhardwaj. (2021). Vaccines for immunoprevention of cancer. Journal of Clinical Investigation. 131(9). 53 indexed citations
15.
Okano, Susumu, Tomohiro Enokida, Takuma Onoe, et al.. (2019). Induction TPF chemotherapy followed by CRT with fractionated administration of cisplatin in patients with unresectable locally advanced head and neck cancer. International Journal of Clinical Oncology. 24(7). 789–797. 14 indexed citations
16.
Tahara, Makoto, et al.. (2018). Clinical Effect of Dose Escalation of Lenvatinib After Disease Progression in Patients With Metastatic Thyroid Cancer. International Journal of Radiation Oncology*Biology*Physics. 100(5). 1384–1385. 1 indexed citations
17.
Enokida, Tomohiro, Shinya Suzuki, Aya Nishizawa, et al.. (2018). Predictive Value of Cetuximab-Induced Skin Toxicity in Recurrent or Metastatic Squamous Cell Carcinoma of the Head and NECK. Frontiers in Oncology. 8. 616–616. 17 indexed citations
18.
Enokida, Tomohiro. (2017). Predictive biomarker. Annals of Oncology. 28. ix17–ix17. 1 indexed citations
19.
Enokida, Tomohiro, Shinya Suzuki, Tetsuro Wakasugi, et al.. (2016). Incidence and Risk Factors of Hypomagnesemia in Head and Neck Cancer Patients Treated with Cetuximab. Frontiers in Oncology. 6. 196–196. 10 indexed citations
20.
Suzuki, Shinya, Tomohiro Enokida, Tetsuro Wakasugi, et al.. (2015). Retrospective analysis of anti-allergy prophylaxis for infusion reactions of cetuximab in head and neck cancer patients. Annals of Oncology. 26. vii136–vii136.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Amy Prawira Breakdown of academic impact, for papers by Yu Heng Breakdown of academic impact, for papers by Wen Gao Breakdown of academic impact, for papers by Antonella Ingrosso Breakdown of academic impact, for papers by Venessa Tsang Breakdown of academic impact, for papers by V. Papadimitrakopoulou Breakdown of academic impact, for papers by Hitomi Suzuki Breakdown of academic impact, for papers by Mariachiara Santorsola Breakdown of academic impact, for papers by Xiuyi Zhi Breakdown of academic impact, for papers by Mary Kate Kasler
Rankless by CCL
2026